. "17910"^^ . "1"^^ . "V\u00FDvoj a inovace nov\u00FDch nanomateri\u00E1l\u016F pro c\u00EDlenou modifikaci c\u00E9vn\u00EDch n\u00E1hrad"@cs . "2015-12-31+01:00"^^ . . . "The proposed project will use the chitosan and chitosan derivatives, hyaluronic acid and their complexes with ions of silver and copper to modify existing collagen vascular grafts and, moreover, we have already developed vascular grafts enriched with adiponectin. We will attempt to prepare vascular grafts with antibacterial treatment, which would further improve the throughput and endothelization. Vascular grafts will be tested in cell cultures, at which we will monitor the growth and viability. We will focus our attention on the impact of chemotherapy, especially doxorubicin, on cell growth on vascular grafts with added value in comparison with conventional grafts. Successful use of research and development project will also bring indirect economic benefits. Introduction of new medical devices to both domestic and foreign markets will increase the competitiveness of the company, which will increase the prestige in the eyes of both the professional community and in the eyes of competitors."@en . . "Development and innovation of new nanomaterials for targeted modification of vascular grafts"@en . "2"^^ . "V p\u0159edkl\u00E1dan\u00E9m projektu budeme pou\u017E\u00EDvat chitosan i deriv\u00E1ty chitosanu, kyselinu hyaluronovou a jejich komplexy s ionty st\u0159\u00EDbra a m\u011Bdi pro modifikaci st\u00E1vaj\u00EDc\u00EDch kolagenov\u00FDch c\u00E9vn\u00EDch n\u00E1hrad a d\u00E1le n\u00E1mi ji\u017E vyvinutou c\u00E9vn\u00ED n\u00E1hradu obohacenou adiponektinem. Budeme se sna\u017Eit p\u0159ipravit c\u00E9vn\u00ED prot\u00E9zu s antibakteri\u00E1ln\u00ED \u00FApravou, kde by byla d\u00E1le zv\u00FD\u0161ena endotelializace a pr\u016Fchodnost. C\u00E9vn\u00ED n\u00E1hrady budeme testovat na bun\u011B\u010Dn\u00FDch kultur\u00E1ch, u kter\u00FDch budeme sledovat r\u016Fst a \u017Eivotnost. Svou pozornost zam\u011B\u0159\u00EDme na vliv cytostatik, p\u0159edev\u0161\u00EDm doxorubicinu, na r\u016Fst bun\u011Bk na c\u00E9vn\u00EDch n\u00E1hrad\u00E1ch s p\u0159idanou hodnotou v porovn\u00E1n\u00ED s b\u011B\u017En\u00FDmi n\u00E1hradami. \u00DAsp\u011B\u0161n\u00E9 vyu\u017Eit\u00ED v\u00FDsledk\u016F v\u00FDzkumn\u00E9ho a v\u00FDvojov\u00E9ho projektu p\u0159inese i nep\u0159\u00EDm\u00E9 ekonomick\u00E9 p\u0159\u00EDnosy. Uveden\u00EDm nov\u00FDch zdravotnick\u00FDch prost\u0159edk\u016F na dom\u00E1c\u00ED i zahrani\u010Dn\u00ED trhy se zv\u00FD\u0161\u00ED konkurenceschopnost spole\u010Dnosti, kter\u00E9 zv\u00FD\u0161\u00ED presti\u017E, jak v o\u010D\u00EDch odborn\u00E9 ve\u0159ejnosti, tak i v o\u010D\u00EDch konkuren\u010Dn\u00EDch firem."@cs . "2011-01-01+01:00"^^ . . . "16"^^ . . . . . "13433"^^ . "0"^^ . "16"^^ . . "Nano- and microparticles; vascular grafts; chitosan; hyaluronic acid; silver; copper; doxorubicin; cell cultures"@en . .